AAAAAA
Results:
1-20
|
Results: 20
Authors:
Schilder, RJ
Gallo, JM
Millenson, MM
Bookman, MA
Weiner, LM
Rogatko, A
Rogers, B
Padavic-Shallers, K
Boente, M
Rosenblum, N
Adams, AL
Ciccotto, S
Ozols, RF
Citation: Rj. Schilder et al., Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy, J CL ONCOL, 19(4), 2001, pp. 1183-1194
Authors:
Ozols, RF
Citation: Rf. Ozols, The current role of gemcitabine in ovarian cancer, SEMIN ONCOL, 28(2), 2001, pp. 18-24
Authors:
Ozols, RF
Citation: Rf. Ozols, Optimum chemotherapy for ovarian cancer, INT J GYN C, 10, 2000, pp. 33-37
Authors:
Langer, CJ
McAleer, CA
Bonjo, CA
Litwin, S
Millenson, M
Kosierowski, R
Blankstein, K
Alexander, R
Ozols, RF
Citation: Cj. Langer et al., Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC), EUR J CANC, 36(2), 2000, pp. 183-193
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
Authors:
Agus, DB
Bunn, PA
Franklin, W
Garcia, M
Ozols, RF
Citation: Db. Agus et al., HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer, SEMIN ONCOL, 27(6), 2000, pp. 53-63
Authors:
Ozols, RF
Citation: Rf. Ozols, Contemporary issues in the management of ovarian cancer, SEMIN ONCOL, 27(3), 2000, pp. 1-2
Authors:
Ozols, RF
Citation: Rf. Ozols, Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer, SEMIN ONCOL, 27(3), 2000, pp. 3-7
Authors:
Ozols, RF
Citation: Rf. Ozols, Management of advanced ovarian cancer consensus summary, SEMIN ONCOL, 27(3), 2000, pp. 47-49
Authors:
Ozols, RF
Citation: Rf. Ozols, The role of gemcitabine in the treatment of ovarian cancer, SEMIN ONCOL, 27(1), 2000, pp. 40-47
Authors:
Ozols, RF
Citation: Rf. Ozols, Ovarian cancer: Current status and future directions, PROG ANTI C, 4, 2000, pp. 135-144
Authors:
Ozols, RF
Citation: Rf. Ozols, Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin, CA J SCI AM, 5(6), 1999, pp. 336-338
Authors:
McGuire, WP
Brady, MF
Ozols, RF
Citation: Wp. Mcguire et al., The Gynecologic Oncology Group experience in ovarian cancer, ANN ONCOL, 10, 1999, pp. 29-34
Authors:
Ozols, RF
Gore, M
Trope, C
Grenman, S
Citation: Rf. Ozols et al., Intraperitoneal treatment and dose-intense therapy in ovarian cancer, ANN ONCOL, 10, 1999, pp. 59-64
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
Schilder, RJ
Johnson, S
Gallo, J
Kindsfather, S
Rogers, B
Bookman, MA
Millenson, MM
Boente, M
Rosenblum, N
Litwin, S
Ozols, RF
Citation: Rj. Schilder et al., Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells, J CL ONCOL, 17(7), 1999, pp. 2198-2207
Authors:
Ozols, RF
Citation: Rf. Ozols, Chemotherapy for ovarian cancer, SEMIN ONCOL, 26(6), 1999, pp. 34-40
Authors:
Langer, CJ
Gandara, DR
Calvert, P
Edelman, MJ
Ozols, RF
Citation: Cj. Langer et al., Gemcitabine and carboplatin in combination: An update of phase I and phaseII studies in non-small cell lung cancer, SEMIN ONCOL, 26(1), 1999, pp. 12-18
Authors:
Ozols, RF
Citation: Rf. Ozols, Paclitaxel plus carboplatin in the treatment of ovarian cancer, SEMIN ONCOL, 26(1), 1999, pp. 84-89
Authors:
Ozols, RF
Citation: Rf. Ozols, Oral etoposide for the treatment of recurrent ovarian cancer, DRUGS, 58, 1999, pp. 43-49
Authors:
McGuire, WP
Ozols, RF
Citation: Wp. Mcguire et Rf. Ozols, Chemotherapy of advanced ovarian cancer (vol 25, pg 340, 1998), SEMIN ONCOL, 25(6), 1998, pp. 707-707
Risultati:
1-20
|